Protocol Ledger

NCT07047612 · Phase II/III · RECRUITING

ICP-332 in Subjects With Non-segmental Vitiligo

Interventional Phase II/III clinical trial protocol NCT07047612 sponsored by Beijing InnoCare Pharma Tech Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-09 Enrollment: 603 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07047612
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)603 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07047612
Protocol FieldVerified Registry Value
NCT IdentifierNCT07047612
Consolidated Lead SponsorBeijing InnoCare Pharma Tech Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment603 participants (ESTIMATED)
Registered Start Date2025-05-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI